Risque de restenose et d'evenements cardiaques apres angioplastie coronaire chez le patient diabetique: reduction par des approches pharmacologiques systemiques.
Nyssen, Anne-Sophie; Legrand, Victor; Scheen, André
2009 • In Revue Médicale de Liège, 64 (4), p. 192-8
[en] Various systemic pharmacological approaches have been evaluated to reduce the risk of restenosis after coronary angioplasty, with or without stent, in the general population and in diabetic patients who are at increased risk for such complication. The aim of the present paper is to describe the effects of the main pharmacological classes on the risk of restenosis, the need for new revascularisation procedures and the incidence of major clinical events (MACE: death, myocardial infarction, revascularisation). We will analyse the role of antiplatelet agents, omega-3 fatty acids, statins, anti-inflammatory compounds, immunomodulators, anti-oxidants, glitazones and, finally, classical antidiabetic drugs such as metformin and insulin. Whenever possible, we will focus our attention on the results obtained in the diabetic population.
Disciplines :
Endocrinology, metabolism & nutrition Cardiovascular & respiratory systems
Author, co-author :
Nyssen, Anne-Sophie ; Université de Liège - ULiège > Département Psychologies Cliniques et Systèmes Humains > Ergonomie et intervention au travail
Legrand, Victor ; Université de Liège - ULiège > Département des sciences cliniques > Cardiologie
Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques
Language :
French
Title :
Risque de restenose et d'evenements cardiaques apres angioplastie coronaire chez le patient diabetique: reduction par des approches pharmacologiques systemiques.
Alternative titles :
[en] Incidence of restenosis and cardiac events after coronary angioplasty in diabetic patients: reduction by systemic pharmacological approaches
Ryden L, Standl E, Bartnik M, et al. - Guidelines on diabetes, pre-diabetes, and cardiovascular diseases : executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J, 2007, 28, 88-136.
Nyssen A, Legrand V, Scheen AJ. - Rapport bénéfice/risque des endoprothèses coronaires pharmaco-actives. 1ère partie : analyse dans la population générale. Rev Med Liège, 2008, 63, 542-548.
Nyssen A, Legrand V, Scheen AJ. - Rapport bénéfice/risque des endoprothèses coronaires pharmaco-actives. 2ème partie : analyse dans la population diabétique. Rev Med Liège, 2008, 63, 654-661.
Legrand V. - Therapy insight : diabetes and drug-eluting stents. Nature Clin Pract, 2007, 4, 143-150.
Boyden TF, Nallamothu BK, Moscucci M, et al. - Meta-analysis of randomized trials of drug-eluting stents versus bare metal stents in patients with diabetes mellitus. Am J Cardiol, 2007, 99, 1399-1402.
Scheen AJ, Warzée F. - Diabetes is still a risk factor for restenosis after drug-eluting stent in coronary arteries. Diabetes Care, 2004, 27, 1840-1841.
Schwartz L, Bourassa MG, Lesperance J, et al. - Aspirin and dipyridamole in the prevention of restenosis after percutaneous coronary intervention. N Engl J Med, 1988, 318, 1714-1719.
Mehta S, Yusuf S, Peters R, et al. - Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet, 2001, 358, 527-533.
Steinhubl SR, Berger PB, Mann JT, et al. - Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA, 2002, 288, 2411-2420.
Lee S, Park S, Kim Y, et al. - Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mallitus. The DECLARE-DIABETES trial. J Am Coll Cardiol, 2008, 51, 1181-1187.
Ahn Y, Jeong M, Jeong J, et al. - Randomized comparison of cilostazol vs clopidogrel after drug-eluting stenting in diabetic patients. Circ J, 2008, 72, 35-39.
Biondi-Zoccai G, Lotrionte M, Anselmino M, et al. - Systematic review and meta-analysis of randomized clinical trials appraising the impact of cilostazol after percutaneous coronary intervention. Am Heart J, 2008, 155, 1081-1089.
Brar SS, Kim J, Brar SK, et al. - Long-term outcomes by clopidogrel duration and stent type in a diabetic population with de novo coronary artery. J Am Coll Cardiol, 2008, 51, 2220-2227.
Ho PM, Fihn SD, Wang L, et al. - Clopidogrel and long-term outcomes after stent implantation for acute coronary syndrome. Am Heart J, 2007, 154, 846-851.
Eisenstein EL, Anstrom KJ, Kong DF, et al. - Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA, 2007, 297, 159-168.
Jenkins DJ, Josse AR, Dorian P, et al. - Heterogeneity in randomized controlled trials of long chain (fish) omega-3 fatty acids in restenosis, secondary prevention and ventricular arrhythmias. J Am Coll Nutr, 2008, 27, 367-378.
Balk EM, Lichtenstein AH, Chung M, et al. - Effects of omega-3 fatty acids on coronary restenosis, intima-media thickness, and exercise tolerance: a systematic review. Atherosclerosis, 2006, 184, 237-246.
Walter DH, Schächinger V, Elsner M, et al. - Effect of statin therapy on restenosis after coronary stent implantation. Am J Cardiol, 2000, 85, 962-968.
Kamishirado H, Inoue T, Sakuma M, et al. - Effects of statins on restenosis after coronary stent implantation. Angiology, 2007, 58, 55-60.
Petronio AS, Amoroso G, Limbruno U, et al. - Simvastatin does not inhibit intimal hyperplasia and restenosis but promotes plaque regression in normocholesterolemic patients undergoing coronary stenting: a randomized study with intravascular ultrasound. Am Heart J, 2005, 149, 520-526.
Nishino M, Hoshida S, Kato H, et al. - Preprocedural statin administration can reduce thrombotic reaction after stent implantation. Circ J, 2008, 72, 232-237.
Iwata A, Miura S, Shirai K, et al. - Lower level of low-density lipoprotein cholesterol by statin prevents progression of coronary restenosis after successful stenting in acute myocardial infarction. Intern Med, 2006, 45, 885-890.
Chan AW, Bhatt DL, Chew DP, et al. - Relation of inflammation and benefit of statins after percutaneous coronary interventions. Circulation, 2003, 107, 1750-1756.
Serruys PW, de Feyter P, Macaya C. - Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA, 2002, 287, 3215-3222.
Chan AW, Bhatt DL, Chew DP, et al. - Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation, 2002, 105, 691-696.
Schömig A, Mehilli J, Holle H, et al. - Statin treatment following coronary artery stenting and one-year survival. J Am Coll Cardiol, 2002, 40, 854-861.
Ferrero V, Ribichini F, Pesarini G, et al. - Glucocorticoids in the prevention of restenosis after coronary angioplasty. Therapeutic potential. Drugs, 2007, 67, 1243-1255.
Versaci F, Gaspardone A, Tomai F, et al. - Immunosuppressive therapy for the prevention of restenosis after coronary artery stent implantation (IMPRESS Study). J Am Coll Cardiol, 2002, 40, 1935-1942.
Koo B, Kim Y, Park K, et al. - Effect of celecoxib on restenosis after coronary angioplasty with a Taxux stent (COREA-TAXUS trial): an open-label randomised controlled study. Lancet, 2007, 370, 567-574.
Rodriguez AE, Fernandez-Pereira C. - Systemic immunosuppressive therapy with oral sirolimus after bare metal stent implantation: the missing alternative in the prevention of coronary restenosis after percutaneous coronary interventions. Recent Patents Cardiovasc Drug Discov, 2008, 3, 201-208.
Douglas JS. - Pharmacologic approaches to restenosis prevention. Am J Cardiol, 2007, 100, 10K-16K.
Tardif J-C, Grégoire J, Schwartz L, et al. - Effects of AGI-1067 and probucol after percutaneous coronary interventions. Circulation, 2003, 107, 552-558.
Scheen AJ, Paquot N. - Récepteurs PPAR-γ, nouvelle cible thérapeutique dans les pathologies métaboliques et cardio-vasculaires. Rev Med Liège, 2005, 60, 89-95.
Scheen AJ, De Flines J, Paquot N. - Le point sur la controverse à propos de la rosiglitazone. Rev Med Liège, 2007, 62, 560-565.
Nathan DM, Buse JB, Davidson MB, et al. - Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 2008, 31, Oct 22. [Epub ahead of print].
Marx N, Wohrle J, Nusser T, et al. - Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in nondiabetic patient. Circulation, 2005, 112, 2792-2798.
Takagi T, Yamamuro A, Tamita K, et al. - Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study. Am Heart J, 2003, 146, e1-e5.
Nishio K, Sakurai M, Kusuyama T, et al. - A randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with type 2 diabetes. Diabetes Care, 2006, 29, 101-106.
Katayama T, Ueba H, Tsuboi K, et al. - Reduction of neointimal hyperplasia after coronary stenting by pioglitazone in non-diabetic patients with metabolic syndrome. Am Heart J, 2007, 153, 762-767.
Cao Z, Zhou Y, Zhao Y, et al. - Rosiglitazone could improve clinical outcome after coronary stent implantation in nondiabetic patients with metabolic syndrome. Chin Med J, 2006, 119, 1171-1175.
Wang G, WeiJ, Guan Y, et al. - Peroxisome proliferators-activated receptor-γ agonist rosiglitazone reduces clinical inflammatory responses in type 2 diabetes with coronary artery disease after coronary angioplasty. Metabolism, 2005, 54, 590-597.
Choi D, Jang Y, Klim S, et al. - Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care, 2004, 27, 2654-2660.
Osman A, Otero J, Brizolara A, et al. - Effect of rosiglitazone on restenosis after coronary stenting in patients with type 2 diabetes. Am Heart J, 2004, 147, e21-25.
Fang C, Jao Y, Yi-Chen, at al. - Angiographic and clinical outcomes of rosiglitazone in patients with type 2 diabetes mellitus after percutaneous coronary interventions: a single center experience. Angiology, 2007, 58, 523-534.
Riche AM, Valderrama R, Henyan NN. - Thiazolidinediones and risk of repeat target vessel revascularization following percutaneous coronary intervention. Diabetes Care, 2007, 30, 384-388.
Rosmarakis ES, Falagas ME. - Effect of thiazolidinedione therapy on restenosis after coronary stent implantation: a meta-analysis of randomized controlled trials. Am Heart J, 2007, 154, 144-150.
Geng D, Jin D, WeiWu, et al. - Effect of thiazolidinediones on in-stent restenosis in patients after coronary stenting: A meta-analysis of randomized controlled trials. Atherosclerosis, 2008, May 28, sous presse.
Rana JS, Monraats PS, Zwinderman A, et al. - Metabolic syndrome and risk of restenosis in patients undergoing percutaneous coronary intervention. Diabetes Care, 2005, 28, 873-877.
Canibus P, Faloia E, Piva T, et al. - Metabolic syndrome does not increase angiographic restenosis rates after drug-eluting stent implantation. Metabolism, 2008, 57, 593-597.
Kao J, Tobis J, McClelland R, et al. - Relation of metformin treatment to clinical events in diabetic patients undergoing percutaneous intervention. Am J Cardiol, 2004, 93, 1347-1350.
Radermecker RP, Philips JC, Jandrain B, et al. - Contrôle glycémique et morbi-mortalité cardio-vasculaire chez le patient diabétique de type 2. Résultats des études ACCORD, ADVANCE et VA-Diabetes. Rev Med Liège, 2008, 63, 511-518.
Scheen AJ, Legrand D. - Platelet dysfunction associated to insulin therapy in patients with type 2 diabetes : please do not throw the baby out with the bath water (Letter). J Am Coll Cardiol, 2007, 49, 628.
Kumar R, Lee TT, Jeremias A, et al. - Comparison of outcomes using sirolimus-eluting stenting in diabetic versus nondiabetic patients with comparison of insulin versus non-insulin therapy in the diabetic patients. Am J Cardiol, 2007, 100, 1187-1191.
Kiernan TJ, Yan BP, Cruz-Gonzalez I, et al. - Pharmacological and cellular therapies to prevent restenosis after percutaneous transluminal angioplasty and stenting. Cardiovasc Hematol Agents Med Chem, 2008, 6, 116-124.
Delcré S, Anselmino M, Moretti C, et al. - Clinical and pharmacological management of a high risk diabetic population undergoing percutaneous coronary interventions. Minerva Cardioangiol, 2008, 53, 267-275.